NCS1 Agonists for Wolfram Syndrome Mitochondrial Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no effective treatment for Wolfram Syndrome, a neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness, with high morbidity and mortality, and current management only addresses symptoms like diabetes mellitus with insulin replacement and diet control.
Innovation Solution
The use of NCS1 agonists, including NCS1-encoding polynucleotides, proteasome inhibitors like MG-132, and calpain inhibitors, to increase NCS1 expression and stabilize it from degradation, thereby mitigating the effects of WFS1 mutations by enhancing mitochondrial function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If WFS1 mutations occur, then wolframin function is lost leading to ER stress and apoptosis, but no effective treatment exists to address the underlying cause
Solution Approach 1:
The patent uses NCS1 as an intermediary molecule to bridge the gap caused by WFS1 mutation. By administering NCS1 agonists, the therapy mediates the protective effect without requiring functional WFS1 protein, thus bypassing the genetic defect while still achieving the desired protective outcome against ER stress and apoptosis
Solution Approach 2:
The patent changes the biochemical parameter of NCS1 activity by introducing agonists that enhance NCS1 function. This parameter change (increasing NCS1 agonist activity) compensates for the loss of WFS1 function, thereby preventing ER stress and apoptosis even when WFS1 is mutated
2Ease of operation
If current symptomatic management is used, then quality of life is maintained to some extent, but it does not address the underlying neurodegenerative process
Solution Approach 1:
The patent applies preliminary action by intervening in the disease pathway before irreversible neurodegeneration occurs. By targeting the underlying mechanism (ER stress and apoptosis) with NCS1 agonists, the treatment prevents disease progression rather than merely managing symptoms after damage has occurred
Solution Approach 2:
The patent converts the harmful effect of WFS1 loss into a beneficial therapeutic opportunity. By identifying that NCS1 can compensate for WFS1 function, the therapy transforms the genetic defect into a targetable pathway where enhancing NCS1 activity provides protective effects that were previously unavailable
Data Source
Figure 1A~1E
Figure 2A~2D
Figure 3A~3D
AI summary
The present invention relates to novel therapeutic ways for treating Wolfram Syndrome (WS) by targeting the neuronal calcium sensor 1 (NCS1). The present inventors have demonstrated that WFS1, which loss of function is responsible of the Wolfram Syndrome, forms a complex with the neuronal calcium sensor 1 (NCS1). The inventors have further demonstrated that WFS1 associates with NCS1 to prevent its degradation by the proteasome and that NCS1 regulates VDAC expression and mitochondrial respiratory chain. Thus, present invention provides an agonist of NCS1 for use in the treatment of WS. Such an agonist is e.g. a NCS1-encoding polynucleotide, an inhibitor of the proteasome or of calpains. The inventors have further shown that overexpression of NCS1 in WS cells allows increasing complex II driven respiration. The present invention further relates to a method for predicting the severity of WS by measuring the NCS1 level in a sample obtained from a patient.